Central Nervous System Stimulants

• 

  Subject Areas on Research

  • "Model" behavior. 
  • "Nothing Is Free": A Qualitative Study of Sex Trading Among Methamphetamine Users in Cape Town, South Africa. 
  • 3-year follow-up of the NIMH MTA study. 
  • A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR®) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder. 
  • A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA). 
  • A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). 
  • A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression. 
  • A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. 
  • A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. 
  • A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD. 
  • A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. 
  • A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder. 
  • A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. 
  • A study of the potential confounding effects of diet, caffeine, nicotine and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia. 
  • ADHD, Smoking Withdrawal, and Inhibitory Control: Results of a Neuroimaging Study with Methylphenidate Challenge. 
  • ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. 
  • Abnormal fronto-limbic engagement in incarcerated stimulant users during moral processing. 
  • Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD). 
  • Activity patterns in mesolimbic regions in rats during operant tasks for reward. 
  • Acute Heart Failure in a 39-Year-Old Man. 
  • Adjustment to college in students with ADHD. 
  • Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. 
  • Advances in the pharmacotherapy of attention-deficit/hyperactivity disorder. 
  • Alcohol use and consequences in matriculating US college students by prescription stimulant/opioid nonmedical misuse status. 
  • Amphetamine trials and tribulations. 
  • Amphetamines and related drugs in motor recovery after stroke. 
  • An evidence-based medicine approach to combined treatment for ADHD in children and adolescents. 
  • An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults. 
  • An observational study of pharmacological treatment in primary care of children with ADHD in the United kingdom. 
  • Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). 
  • Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. 
  • Assessing medication effects in the MTA study using neuropsychological outcomes. 
  • Assessing methylphenidate preference in ADHD patients using a choice procedure. 
  • Assessment of brain activity during memory encoding in a narcolepsy patient on and off modafinil using normative fMRI data. 
  • Attenuation of pharmacologically-induced attentional impairment by methylphenidate in rats. 
  • Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. 
  • Caffeine affects cardiovascular and neuroendocrine activation at work and home. 
  • Caffeine deprivation affects vigilance performance and mood. 
  • Caffeine withdrawal symptoms following brief caffeine deprivation. 
  • Can methylphenidate objectively provide relief in patients with uncontrolled blepharospasm? A pilot study using surface electromyography. 
  • Child and parent predictors of perceptions of parent--child relationship quality. 
  • Clinical presentation of attention-deficit/hyperactivity disorder in preschool children: the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). 
  • Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. 
  • Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. 
  • Comments on 'Cytogenetic effects in children treated with methylphenidate' by El-Zein et al. 
  • Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). 
  • Comparing pharmacological treatments for cocaine dependence: Incorporation of methods for enhancing generalizability in meta-analytic studies. 
  • Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. 
  • Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. 
  • Comprehensive versus matched psychosocial treatment in the MTA study: conceptual and empirical issues. 
  • Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. 
  • Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. 
  • Deficiency of Shank2 causes mania-like behavior that responds to mood stabilizers. 
  • Desensitization of G protein-coupled receptors and neuronal functions. 
  • Design considerations for a study to evaluate the impact of smoking cessation treatment on stimulant use outcomes in stimulant-dependent individuals. 
  • Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice. 
  • Discriminative and participant-rated effects of methylphenidate in children diagnosed with attention deficit hyperactivity disorder (ADHD). 
  • Dissociable roles for the basolateral amygdala and orbitofrontal cortex in decision-making under risk of punishment. 
  • Dopaminergic abnormalities in Hdac6-deficient mice. 
  • Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. 
  • Dose response effects of lisdexamfetamine dimesylate treatment in adults with ADHD: an exploratory study. 
  • Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. 
  • Drug use and validity of substance use self-reports in veterans seeking help for posttraumatic stress disorder. 
  • EEG, physiology, and task-related mood fail to resolve across 31 days of smoking abstinence: relations to depressive traits, nicotine exposure, and dependence. 
  • Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. 
  • Effect of Dextroamphetamine on Poststroke Motor Recovery: A Randomized Clinical Trial. 
  • Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). 
  • Effects of brief caffeinated-beverage deprivation on mood, symptoms, and psychomotor performance. 
  • Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. 
  • Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. 
  • Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. 
  • Effects of methylphenidate on sensitivity to reinforcement in children diagnosed with attention deficit hyperactivity disorder: an application of the matching law. 
  • Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. 
  • Effects of training dose on the relationship between discriminative-stimulus and self-reported drug effects of d-amphetamine in humans. 
  • Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study. 
  • Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. 
  • Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting. 
  • Emergency/Adjunct services and attrition prevention for randomized clinical trials in children: the MTA manual-based solution. 
  • Emerging drugs for attention-deficit/hyperactivity disorder. 
  • Emerging pharmacotherapy for cancer patients with cognitive dysfunction. 
  • Enantioselective determination of methylphenidate and ritalinic acid in whole blood from forensic cases using automated solid-phase extraction and liquid chromatography-tandem mass spectrometry. 
  • Enduring behavioral effects of early exposure to methylphenidate in rats. 
  • Epigenetics and psychostimulant addiction. 
  • Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. 
  • Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. 
  • Failure to suppress low-frequency neuronal oscillatory activity underlies the reduced effectiveness of random patterns of deep brain stimulation. 
  • Family processes and treatment outcome in the MTA: negative/ineffective parenting practices in relation to multimodal treatment. 
  • Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. 
  • Follow-Up of Young Adults With ADHD in the MTA: Design and Methods for Qualitative Interviews. 
  • Frequency-dependent, transient effects of subthalamic nucleus deep brain stimulation on methamphetamine-induced circling and neuronal activity in the hemiparkinsonian rat. 
  • Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. 
  • G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice. 
  • HIV testing behaviors and attitudes among community recruited methamphetamine users in a South African township. 
  • Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. 
  • Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. 
  • Individual differences in psychostimulant responses of female rats are associated with ovarian hormones and dopamine neuroanatomy. 
  • Injection drug use among stimulant users in a national sample. 
  • Lack of consistent sex differences in D-amphetamine-induced dopamine release measured with [¹⁸ F]fallypride PET. 
  • Lisdexamfetamine Dimesylate (Vyvanse) for the Treatment of Neurogenic Anejaculation. 
  • Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. 
  • Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. 
  • Long-term efficacy of methylphenidate in enhancing attention regulation, social skills, and academic abilities of childhood cancer survivors. 
  • Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder. 
  • MDMA "ecstasy" alters hyperactive and perseverative behaviors in dopamine transporter knockout mice. 
  • Magnitude and ethanol sensitivity of tonic GABAA receptor-mediated inhibition in dentate gyrus changes from adolescence to adulthood. 
  • MeCP2 in the nucleus accumbens contributes to neural and behavioral responses to psychostimulants. 
  • MeCP2 phosphorylation limits psychostimulant-induced behavioral and neuronal plasticity. 
  • Mecamylamine increases cigarette smoking in psychiatric patients. 
  • Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. 
  • Mediators of interpersonal violence and drug addiction severity among methamphetamine users in Cape Town, South Africa. 
  • Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. 
  • Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. 
  • Menthol disrupts nicotine's psychostimulant properties in an age and sex-dependent manner in C57BL/6J mice. 
  • Methamphetamine use is associated with childhood sexual abuse and HIV sexual risk behaviors among patrons of alcohol-serving venues in Cape Town, South Africa. 
  • Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression. 
  • Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD. 
  • Methylphenidate does not influence smoking-reinforced responding or attentional performance in adult smokers with and without attention deficit hyperactivity disorder (ADHD). 
  • Methylphenidate effects on functional outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). 
  • Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial. 
  • Methylphenidate increases willingness to perform effort in adults with ADHD. 
  • Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. 
  • Methylphenidate-induced autoimmune hepatitis. 
  • Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. 
  • Misuse of methamphetamine and prescription stimulants among youths and young adults in the community. 
  • Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. 
  • Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. 
  • Modulation of decompression sickness risk in pigs with caffeine during H(2) biochemical decompression. 
  • More Evidence That Caffeine Consumption Appears to Be Safe in Patients With Heart Failure. 
  • Neural cell adhesion molecule-secreting transgenic mice display abnormalities in GABAergic interneurons and alterations in behavior. 
  • Nicotine-antipsychotic drug interactions and attentional performance in female rats. 
  • On chronic fatigue syndrome. 
  • PPI deficit induced by amphetamine is attenuated by the histamine H1 antagonist pyrilamine, but is exacerbated by the serotonin 5-HT2 antagonist ketanserin. 
  • Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. 
  • Parent versus teacher ratings of attention-deficit/hyperactivity disorder symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). 
  • Parenting and family stress treatment outcomes in attention deficit hyperactivity disorder (ADHD): an empirical analysis in the MTA study. 
  • Pediatric narcolepsy. 
  • Peer-assessed outcomes in the multimodal treatment study of children with attention deficit hyperactivity disorder. 
  • Performance-enhancing drugs. 
  • Persistent behavioral impairment caused by embryonic methylphenidate exposure in zebrafish. 
  • Pharmacogenetics of methylphenidate response in preschoolers with ADHD. 
  • Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy. 
  • Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate. 
  • Pharmacotherapy of the Preschool ADHD Treatment Study (PATS) Children Growing Up. 
  • Poststroke treatment: lost in translation. 
  • Postsynaptic Mechanisms Render Syn I/II/III Mice Highly Responsive to Psychostimulants. 
  • Predictors of nonmedical ADHD medication use by college students. 
  • Psychopharmacological interactions between nicotine and ethanol. 
  • Psychopharmacological treatment for very young children: contexts and guidelines. 
  • Psychosocial treatments for preschool-aged children with Attention-Deficit Hyperactivity Disorder. 
  • Psychostimulant dependence in a community sample. 
  • Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS). 
  • Recent advances in poststroke depression. 
  • Recommendations for high-priority research on cancer-related fatigue in children and adults. 
  • Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). 
  • Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence. 
  • Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder. 
  • Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. 
  • Safety and tolerability of methylphenidate in preschool children with ADHD. 
  • Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. 
  • Selective deletion of GRK2 alters psychostimulant-induced behaviors and dopamine neurotransmission. 
  • Sex differences in novelty- and psychostimulant-induced behaviors of C57BL/6 mice. 
  • Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. 
  • Stimulant prescription cautions: addressing misuse, diversion and malingering. 
  • Stimulant reduction intervention using dosed exercise (STRIDE) - CTN 0037: study protocol for a randomized controlled trial. 
  • Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design. 
  • Stimulant treatment for children: a community perspective. 
  • Stimulant treatment of ADHD and cigarette smoking: a meta-analysis. 
  • Subjective effects and changes in steroid hormone concentrations in humans following acute consumption of alcohol. 
  • Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection. 
  • The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study. 
  • The dopamine transporter: a crucial component regulating dopamine transmission. 
  • The effects of environmental noise and infant position on cerebral oxygenation. 
  • The misuse and diversion of prescribed ADHD medications by college students. 
  • The role of substance use coping in the relation between childhood sexual abuse and depression among methamphetamine users in South Africa. 
  • The what, where, and when of catechol-O-methyltransferase. 
  • Tobacco smoking and other suspected antecedents of nonmedical psychostimulant use in the United States, 1995. 
  • Treatment-related changes in objectively measured parenting behaviors in the multimodal treatment study of children with attention-deficit/hyperactivity disorder. 
  • Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. 
  • Which treatment for whom for ADHD? Moderators of treatment response in the MTA. 
  • Wide variation in caffeine discontinuation timing in premature infants. 
• 

  Keywords of People

  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine